Kyntra Bio Reports Q3 2026 Results and Strategic Pivot to Rare Disease Focus

Kyntra Bio (KYNB) has announced a strategic restructuring into a pure-play rare disease company following the termination of its FG-3246 and FG-3180 oncology programs. While the decision to end these programs was driven by clinical benchmarks, it is expected to generate over $20 million in operating expense savings through 2028. The company also successfully restructured its debt and royalty obligations, reducing maximum aggregate payments to NovaQuest Capital Management from $125 million to $65 million. The company's primary focus shifts to roxadustat for myelodysplastic syndromes (MDS), which showed significant efficacy in the MATTERHORN study. Kyntra Bio plans to initiate Phase 3 trials in Q1 2027, contingent on securing a strategic partnership or external capital. With $44.1 million in cash and liquidity, management expects a cash runway extending into 2028.

7 articles from 3 sources · updated

Coverage